Beijing Key Laboratory of Electrochemical Process and Technology of Materials, School of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing 100029, China.
State Key Laboratory of Organic-Inorganic Composites, School of Chemical Engineering, School of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing 100029, China.
Int J Mol Sci. 2022 Jan 22;23(3):1227. doi: 10.3390/ijms23031227.
Two key concerns exist in contemporary cancer chemotherapy in clinic: limited therapeutic efficiency and substantial side effects in patients. In recent years, researchers have been investigating a revolutionary cancer treatment technique, and photodynamic therapy (PDT) has been proposed by many scholars. A drug for photodynamic cancer treatment was synthesized using the hydrothermal method, which has a high efficiency to release reactive oxygen species (ROS). It may also be utilized as a clear multi-modality bioimaging platform for photoacoustic imaging (PAI) due to its photothermal effect, computed tomography (CT), and magnetic resonance imaging (MRI). When compared to single-modality imaging, multi-modality imaging delivers far more thorough and precise details for cancer diagnosis. Furthermore, Au-doped up-conversion nanoparticles (UCNPs) have an exceptionally high luminous intensity. The Au-doped UCNPs, in particular, are non-toxic to tissues without laser at an 808 nm wavelength, endowing the as-prepared medications with outstanding therapeutic efficacy but exceptionally low side effects. These findings may encourage fresh effective imaging-guided approaches to meet the goal of photodynamic cancer therapy to be created.
在当代癌症化疗临床中存在两个主要问题:患者的治疗效率有限和严重的副作用。近年来,研究人员一直在探索一种革命性的癌症治疗技术,光动力疗法(PDT)已经被许多学者提出。一种用于光动力癌症治疗的药物是通过水热法合成的,该方法具有高效释放活性氧(ROS)的特点。由于其光热效应、计算机断层扫描(CT)和磁共振成像(MRI),它也可用作清晰的多模态生物成像平台用于光声成像(PAI)。与单模态成像相比,多模态成像为癌症诊断提供了更全面、更精确的细节。此外,金掺杂上转换纳米粒子(UCNPs)具有极高的发光强度。特别是金掺杂的 UCNPs 在 808nm 波长的激光下对组织无毒,赋予了所制备的药物优异的治疗效果和极低的副作用。这些发现可能会鼓励新的有效的成像引导方法的创建,以实现光动力癌症治疗的目标。
Int J Mol Sci. 2022-1-22
Int J Mol Sci. 2022-4-13
ACS Appl Mater Interfaces. 2021-3-10
Am J Cancer Res. 2023-12-15
Front Pharmacol. 2023-9-28
Pharmaceutics. 2023-3-22
Nanomaterials (Basel). 2022-2-22
Nanomaterials (Basel). 2021-12-15
Nanotechnology. 2021-8-4
Biomedicines. 2021-6-29
J Colloid Interface Sci. 2021-10-15
Nanotechnology. 2009-9-30